We tested hypothesis that activation of the prostacyclin (PGI 2 ) receptor (IP receptor) signaling pathway in cerebral microvessels plays an important role in the metabolism of amyloid precursor protein (APP). In human brain microvascular endothelial cells activation of IP receptor with the stable analogue of PGI 2 , iloprost, stimulated expression of amyloid precursor protein and a disintegrin and metalloprotease 10 (ADAM10), resulting in an increased production of the neuroprotective and anticoagulant molecule, soluble APPa (sAPPa). Selective agonist of IP receptor, cicaprost, and adenylyl cyclase activator, forskolin, also enhanced expression of amyloid precursor protein and ADAM10. Notably, in cerebral microvessels of IP receptor knockout mice, protein levels of APP and ADAM10 were reduced. In addition, iloprost increased protein levels of peroxisome proliferator-activated receptor d (PPARd) in human brain microvascular endothelial cells. PPARd-siRNA abolished iloprost-augmented protein expression of ADAM10. In contrast, GW501516 (a selective agonist of PPARd) upregulated ADAM10 and increased production of sAPPa. Genetic deletion of endothelial PPARd (ePPARd À/À ) in mice significantly reduced cerebral microvascular expression of ADAM10 and production of sAPPa. In vivo treatment with GW501516 increased sAPPa content in hippocampus of wild type mice but not in hippocampus of ePPARd À/À mice. Our findings identified previously unrecognized role of IP-PPARd signal transduction pathway in the production of sAPPa in cerebral microvasculature.
Introduction
Vascular protective effects of prostacyclin (PGI 2 ) are essential for the preservation of cerebrovascular homeostasis and hemostasis. [1] [2] [3] [4] The endothelium is a major source of PGI 2 which is generated in response to a number of different stimuli including vascular injury. 5-7 PGI 2 is a potent vasodilator; it stimulates angiogenesis and preserves barrier function of endothelial cells. 8, 9 Furthermore, PGI 2 analogues attenuate brain damage caused by ischemic stroke, 10 suggesting that activation of PGI 2 receptors (IP receptors) is an important neuroprotective mechanism. In addition, PGI 2 also exerts an inhibitory effect on blood coagulation by activation of IP receptors coupled to adenylyl cyclase and increased formation of cyclic AMP in circulating platelets. 6, 9 Amyloid precursor protein (APP) is a member of a family of evolutionarily conserved single-pass type I transmembrane glycoproteins. 11 Three major isoforms of APP (APP695, APP751, and APP770) have been identified. APP 751 and APP770 contain a domain homologous to Kunitz-type protein inhibitors (KPI). 12 We have reported that APP is highly expressed in endothelium. 13 It has also been demonstrated that brain microvascular endothelial cells primarily express very high levels of APP770 containing KPI domain. 12 APP770 and soluble APP770 (sAPP770) that contains the KPI domain may protect the brain from cerebrovascular thrombosis by inhibition of prothrombotic proteinase factor Xla. 12, [14] [15] [16] Thus, both PGI 2 and APP protect cerebral vasculature against thrombosis; however, to date the functional relationship between these two molecules has not been studied. In the present study we tested the hypothesis that activation of the IP receptor signal transduction pathway in cerebral microvessels plays an important role in metabolism of APP.
Once expressed, APP is subsequently cleaved by two different pathways. The amyloidogenic pathway generates cytotoxic Ab, which is considered a major culprit in the pathogenesis of Alzheimer's disease. In the nonamyloidogenic pathway APP is cleaved by a-secretases within the Ab sequence thereby generating soluble APPa (sAPPa) ectodomain. Under physiological conditions, a-processing of APP is a dominant pathway, producing sAPPa, a well-known neurotrophic and neuroprotective molecule. [17] [18] [19] [20] [21] Of note, sAPP770 has stronger in vitro neurotrophic effect than neuronal isoform sAPP695. 22 In vivo studies have also revealed an important role of sAPPa in cognitive function such as memory, and maintenance of normal brain structure and electrophysiological function. 17, 23, 24 Interestingly, elevated levels of KPI-containing APP have been observed in brain tissue exposed to ischemia and neurotoxic damage, [25] [26] [27] [28] indicating a possible neuro-vascular protective effect of endothelial APP under pathological conditions. Indeed this concept has been reinforced by the findings that inflammatory cytokines stimulate release of sAPPa770 from endothelial cells. 29 Thus, endothelial sAPPa might play a critical role in neurovascular protection in response to ischemia and inflammatory insults. Therefore, understanding mechanisms underlying regulation of sAPPa production in cerebral vascular endothelial cells is of major importance for the development of therapeutic targets in prevention and treatment of stroke and brain injury.
Peroxisome proliferator-activated receptor d (PPARd) is a ligand-activated transcription factor that belongs to the nuclear receptor super-family which includes two additional isoforms PPARa and PPARg. 30 Besides their role in the control of metabolism, PPAR isoforms are essential regulators of cardiovascular system. 30 Prior studies suggest that systemic activation of PPARd is protective against major cardiovascular risk factors including dyslipidemia, insulin resistance, and obesity. 30 In peripheral blood vessels, pharmacological analysis demonstrated that PPARd agonists exert vascular protective effects 13, 31, 32 ; however, the role of PPARd in cerebral vascular function is not fully understood. In our previous study we demonstrated that in the cerebral microvessels, activation of PPARd prevented endothelial dysfunction thereby suggesting that endothelial PPARd might be an important vasoprotective molecule. 33 We also established that in endothelial specific PPARd knockout (ePPARd À/À ) mice oxidative stress is a major factor leading to peripheral vascular dysfunction. 32 Since our prior studies suggest that PPARd could mediate PGI 2 -induced endothelial regeneration, 31 the present study was also designed to determine the role of PPARd in PGI 2 -dependent regulation of APP expression and metabolism.
Material and methods Mice
Use of the animals and protocols were approved by the Institutional Animal Care and Use Committee of the Mayo Clinic. Mice homozygous for deletion of IP receptor (IP À/À mice) were generously provided by Dr. Garret A. FitzGerald (University of Pennsylvania, Philadelphia, PA), 34 and bred with C57BL/6 J mice (Jackson Laboratory) to generate mice heterozygous for deletion of IP receptor. The IP À/À mice and wild type littermates (2-3 months old, males and females) generated from breeder mice heterozygous for deletion of IP receptor were used in experiments. Mice with endothelial-specific knock-down PPARd (ePPARd À/À mice) and their wild type littermates were kindly provided to us by Dr. Ronald. M. Evans (The Salk Institute, La Jolla, CA) and bred in our laboratory. 32 Male mice (3-5 months old) were maintained on standard chow with free access to drinking water. ePPARd À/À and wild type mice were orally gavaged with GW501516 (2 mg/kg/day) or vehicle (0.5% carboxy methyl cellulose in 2% dimethylsulfoxide, control group) for 14 days. This dose was chosen based on the results of the previous in vivo studies demonstrating selectivity of GW501516 as a PPARd agonist. 33, 35 Investigator was not blinded as to which mouse belonged to control group and which belonged to treated group. Brain tissues were collected after mice were killed by injection of an overdose of pentobarbital (250 mg/kg body weight, i.p.). The experiments were performed in accordance with the ARRIVE guidelines. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Vascular reactivity
Organ chambers were used for recording isometric force of isolated aortic rings as described previously. 32 Relaxations to cicaprost were obtained in aortas of wild-type and IP À/À mice during submaximal contractions to phenylephrine.
Isolation of cerebral microvessels
Isolation of cerebral microvessels was performed as described in our previous studies. 33 Briefly, mouse brain was removed and placed in cold (4 C) modified Krebs-Ringer bicarbonate solution (in mmol/L: NaCl 118.6; KCl 4.7; CaCl 2 2.5; MgSO 4 1.2; KH 2 PO 4 1.2; NaHCO 3 25.1; glucose 10.1; EDTA 0.026). Under a surgical microscope, anterior and posterior cerebral, middle cerebral and basilar arteries were removed. Cerebral microvessels were then isolated from whole brain or brain hemisphere using 15% Dextran (Sigma-Aldrich, St. Louis, MO) centrifugation. The isolated microvessels contained a heterogeneous mixture of small arteries, arterioles, capillaries, small veins, and venules. 33 
Isolation of mouse cerebral microvascular endothelial cells
Primary mouse brain endothelial cells were obtained as described 36 with minor modification. After brain microvessels were isolated, the pellet was suspended in endothelial basal medium 2 (EBM2) (Lonza, Allendale, NJ) containing 1 mg/ml collagenase/dispase (Roche, Indianapolis, IN), 1000 U/ml DNase 1 (Roche), and 0.147 mg/ml tosyllysine chloromethyl ketone (Sigma-Aldrich, St. Louis, MO) and incubated at 37 C for 75 min with occasional shaking. The digest was centrifuged at 2000 g for 5 min, and cells were washed with endothelial growth medium 2 (EGM2, Lonza), and seeded in 24-well plates coated with mouse collagen IV (BD Biosciences, San Jose, CA). Cells were cultured in EGM2 þ15% FCS. To deplete the cells of nonendothelial origin, puromycin (4 mg/ml, Sigma-Aldrich St. Louis, MO) was added to the culture for the first 48 h. After culturing for 8 days, cells were collected for characterization. For fluorescent confocal microscopy, cells were seeded on 4-well glass chamber slide system. Immunofluorescent confocal microscopy analysis was performed as described in our previous studies, 37 using mouse antibody against PECAM-1 (1:100 dilution, Santa Cruz Biotechnology, Dallas, TX).
Western blot analysis
Western blotting was performed as previously described. 38 Cerebral microvessels were homogenized in lysis buffer containing (50 mmol/L NaCl, 50 mmol/L NaF, 50 mmol/L sodium pyrophosphate, 5 mmol/L EDTA, 5 mmol/L EGTA, 0.1 mmol/L Na 3 VO 4 , 1% Triton X-100, 10 mmol/L HEPES, pH 7.4, and protease inhibitor cocktail (Sigma, St. Louis, MO)). Rabbit antibodies against APP, and b-site APP cleaving enzyme 1 (BACE1) were obtained from Invitrogen (Carlsbad, CA), and Abcam (Cambridge, MA), respectively. Rabbit antibody against a disintegrin and metalloprotease 9 (ADAM9), and mouse antibody against sirtuin 1 (SIRT1) were obtained from Cell Signaling Technology (Danvers, MA). Rabbit antibodies against ADAM10 and ADAM17 were obtained from Chemicon International (Temecula, CA). Rabbitanti-PPARd was obtained from Santa Cruz Biotechnology. Blots probed with goat-anti-actin (Santa Cruz Biotechnology) were used as loading controls. Protein expression was normalized to actin. For a-secretase, the protein levels of mature ADAM10, mature ADAM17, and mature ADAM9 (lower bands on the blots) were quantified. Mouse anti-soluble APPa antibody (2B3) was purchased from Immuno-Biological Laboratories (Minneapolis, MN).
cAMP measurement
Cerebral microvessels were isolated and incubated in Krebs-Ringer bicarbonate solution containing 5 mM cicaprost (for microvessels of right hemisphere) or DMSO (vehicle, for microvessels of left hemisphere) at 37 C for 30 min. The microvessel lysates were prepared for measuring cAMP levels using colorimetric cAMP ELISA Kit (Cell Biolabs, San Diego, CA). The samples were acetylated before the assay according to manufacturer's protocol.
Quantitative real-time polymerase chain reaction and RT-PCR
Quantitative real time polymerase chain reaction (PCR) was performed as previously described. 39 For in vitro experiments, primary human brain cerebral cortex microvascular endothelial cells (BMECs, Applied Cell Biology Research Institute, Kirkland, WA) were used at passages 4-6. After human BMECs were treated with iloprost (Cayman Chemical, Ann Arbor MI) or GW501516 (Cayman Chemical) for 57 h, total cellular RNA was isolated using RNeasy Plus Mini kit (Qiagen, Redwood City, CA), and reverse transcription of RNA to cDNA was performed using SuperScript III First-Strand Synthesis System kit (Invitrogen). The amounts mRNA were determined (in triplicate for each sample) using iCycler IQ Real Time Detection System (Bio-Rad, Hercules, CA). The primers 40 corresponding to human ADAM10 mRNA were forward (5 0 TTTGAAGGATTCATCCAGACTC3 0 ) and reverse (5 0 ACACCAGTCATCTGGTATTTCC3 0 ).
Internal control human GAPDH mRNA was amplified with forward (5 0 AAAACCTGCCAAATATGATGAC3 0 ) and reverse (5 0 CAGGAAATGAGCTTGACAAAG T3 0 ) primers. To determine mRNA levels in cerebral microvessels of ePPAR À/À mice and wild type mice in vivo, primers for mouse ADAM10 41 were used: forward (5 0 AATTCTGCTCCTCTCCTGGG3 0 ), and reverse (5 0 ACGCTGGTGTTTTTGGTGTA3 0 ). Mouse GAPDH primers are: forward (TGCCAAGGCT GTGGGCAAGG3 0 ), and reverse (5 0 TGGGCCCTCA GATGCCTGCT3 0 ).
RT-PCR was performed to confirm endothelial deletion of PPARd in ePPAR À/À mice. Primers for mouse PPARd, eNOS, and GAPDH were used as described in our previous publication. 32 Knockdown of PPAR and SIRT1 by small interfering RNA (siRNA) Experiments were performed as described in our previous studies by use of Lipofectamine 2000 (Invitrogen). 39 PPARd-siRNA targeting human PPARd mRNA (ON-TARGETplus SMART pool), and Control-siRNA (ON-TARGETplus Non-targeting siRNA#1) were obtained from Dharmacon (Lafayette, CO). Human BMECs were treated with PPARd-siRNA or Ct-siRNA 30 nM for five days. The protein samples were then collected for Western blot. In some experiments, cells were treated with PPARd-siRNA or Ct-siRNA for 2 days, followed by addition of iloprost to the culture for 3 days. For knock-down of SIRT1, cells were treated with SIRT1-siRNA (ON-TARGETplus human SIRT1 siRNA-SMART pool, from Thermo Scientific), or Control-siRNA-A (Santa Cruz Biotechnology) (50 nM) for 2 days. Then cells were incubated in GW501516 (100 nM) for 3 days, and protein samples were collected.
ELISA for sAPP, A42, and A40
Human BMECs were incubated with EGM2 containing iloprost or GW501516, or EGM2 alone for 48 h. Then cells were incubated in EBM2þ0.5% FCS containing iloprost or GW501516, or EBM2 þ 0.5% FCS for 24 h. Supernatants were collected for assay of sAPPa, using human sAPPa high sensitive assay kit (Immuno-Biological Laboratories-America, Minneapolis, MN). The supernatants were also subjected to assay for Ab40 and Ab42 using human Ab40 ELISA kit and human Ab42 ELISA kit (Invitrogen, Camarillo, CA). Microvessels isolated from whole brain were incubated in 200 ml EBM2 containing 0.1% BSA for 24 h. The supernatants were then collected and subjected to measurement of sAPPa using mouse/rat sAPPa high sensitive assay kit (Immuno-Biological Laboratories-America) according to the manufacturer's protocol.
Statistical analysis
Data are presented as mean AE SEM. Differences between mean values of multiple groups were analyzed using 1-way ANOVA followed by the Tukey test (SigmaStat 12.0 for Windows). Unpaired Student t-test was used to analyze comparison between two groups. P < 0.05 was considered statistically significant.
Results
To determine the role of PGI 2 in APP processing, we first examined the effects of the stable analogue of PGI 2 , iloprost, in cultured human BMECs. Iloprost treatment caused concentration-dependent increase in protein expression of APP (Figure 1(a) ). The time course experiments demonstrated that treatment with iloprost for 48-72 h, but not 24 h, increased APP protein levels (Figure 1(b) ). Iloprost also significantly augmented APP mRNA levels (Figure 1(c) ). We further determined expressions of ADAM9, 10, and 17, since these three metalloproteases of the ADAM family have been suggested to exert a-secretase activity in metabolism of APP. 17, [40] [41] [42] Iloprost treatment for three days increased ADAM10 protein expression in a concentration dependent manner (Figure 1(d) and (e)). Incubation of cells with iloprost enhanced mRNA levels of ADAM10 (Figure 1(f) ). The expression of ADAM 9, ADAM17, or BACE1 was not significantly altered in response to iloprost treatment (Suppl. Figure 1 (A) to (C)). Effects of iloprost on expression and processing of APP led to increased sAPPa formation, but did not affect production of Ab 40 and Ab 42 (Figure 1 (g) and (h)).
Since IP receptors are coupled to activation of adenylyl cyclase and generation of cyclic AMP, in the next series of experiments we examined the effects of forskolin (an adenylyl cyclase activator) and cicaprost (a selective agonist of IP receptor) on expression and processing of APP. Treatment of human BMECs with forskolin or cicaprost stimulated expression of APP and ADAM10 (Figure 2 (a) to (d)). To validate the in vivo relevance of the findings observed in cultured human BMECs, we next performed studies in cerebral microvessels derived from IP À/À mice. The phenotype of IP À/À mice was confirmed by the experiment demonstrating that relaxation of aorta to cicarprost was abolished in IP À/À mice (Suppl. Figure 2 (A) and (B)). In addition, in isolated brain microvessels of WT mice, cicaprost significantly increased cAMP levels; however, Ct brain microvessels of IP À/À mice failed to respond to cicaprost stimulation (Suppl. Figure 2 (C) and (D)). Consistent with findings in cultured human BMECs, protein levels of APP and ADAM10 were significantly reduced in the brain microvessels of IP À/À mice (Figure 2 (e) and (f)). Protein expression of BACE1, ADAM9, and ADAM17 were not changed (Suppl. Figure 3 (A) to (C)). Since hippocampal neuronal loss Cerebral microvessels were isolated from IP À/À and littermate WT mice, and protein samples were subjected to Western blot. n ¼ 10, *P < 0.05, compared to WT mice. and cognitive dysfunction have been observed in IP À/À mice after brain ischemic injury, 43, 44 we further examined the sAPPa levels in hippocampus. As shown in Suppl. Figure 3 (D), sAPPa protein was significantly reduced in hippocampus of IP À/À mice. Thus, our findings suggest that activation of IP receptors and the subsequent increase in cAMP stimulate expression and a-processing of APP. Because cAMP signaling has been shown to activate PPARd, 45, 46 it is possible that PPARd plays a role in the effect of iloprost on APP processing. Indeed, iloprost treatment increased PPARd protein expression ( Figure 3(a) ). Moreover, PPARd-siRNA abolished the stimulatory effect of iloprost on expression of ADAM10 (Figure 3(b) ), suggesting that PPARd plays a major role in mediating the iloprost-induced expression of ADAM10. To further examine the contribution of PPARd in regulation of expression of APP and its processing enzymes, we treated human BMECs with the PPARd selective agonist, GW501516, for three days. We observed that GW501516 stimulated ADAM10 expression (Figure 4(a) and (b)), but did not affect APP protein levels (Figure 4(c) ). Moreover, the sAPPa production was increased in response to GW501516 treatment (Figure 4(d) ). Shorter duration of treatment with GW501516 (for 24-48 h) did not significantly change ADAM10 expression (n ¼ 5-7, data not shown), consistent with time lines of the effects of iloprost on ADAM10. GW501516 did not affect protein levels of ADAM9, ADAM17, and BACE1 (Suppl. Figure 4 (a) to (c)). Deletion of PPARd using siRNA reduced ADAM10 protein levels (Figure 4(e) ), but did not significantly change expression of APP (Figure 4(f) ), ADAM9, ADAM17, or BACE1 (Suppl. Figure 4 (D) to (F)). Therefore, activity of PPARd in human BMECs appears to be involved only in regulation of ADAM10 but not APP expression. In addition, we tested the effect of PPARa agonist WY14643 and PPARg agonist rosiglitazone on ADAM10 expression in human BMECs. As shown in Suppl. Figure 5 (A), WY14643 had no effect on ADAM10 protein expression, whereas rosiglitazone significantly reduced ADAM10 protein expression. Moreover, PPARd-siRNA did not affect protein expression of PPARa and PPARg (Suppl. Figure 5 (B) and (C)). These results indicate that the regulatory role of PPARd in expression of ADAM10 is not dependent on other two isoforms.
To further investigate the role of PPARd in APP processing in vivo, we used ePPARd À/À mice, in which PPARd is exclusively deleted in the endothelium. 32 Here we confirmed that PPARd was knockeddown in the endothelium of cerebral microvessels derived from ePPARd À/À mice. In cultured cerebral microvascular endothelial cells of ePPARd À/À mice PPARd mRNA was deleted (Suppl. Figure 6 (A) and (B)). Furthermore, in isolated cerebral microvessels of ePPARd À/À mice, the mRNA levels of PPARd were also decreased, as compared to that of cerebral microvessels derived from WT littermates (Suppl. Figure 6(C) ). The incomplete deletion of PPARd in microvessels of ePPARd À/À mice most likely reflects presence of other cells such as smooth muscle cells in the isolated cerebral microvessel preparation. Most importantly, in isolated microvessels of ePPARd À/À mice, the levels of ADAM10 protein and mRNA were significantly reduced, as compared to WT littermates ( Figure 5(a) and (b) ). Interestingly, the protein level of ADAM17 was increased in isolated microvessels of ePPARd À/À mice ( Figure 5(c) ). But, protein expression of ADAM9, BACE1, and APP was not significantly changed by deletion of PPARd in cerebrovascular endothelium ( Figure 5 release of sAPPa from isolated brain microvessels of ePPARd À/À mice was significantly reduced ( Figure 5(g) ).
Most notably, sAPPa protein level was significantly reduced in hippocampus of ePPARd À/À mice, as compared to WT mice ( Figure 5(h) ). Endothelial knockdown of PPARd did not affect sAPPa levels in cortex and cerebellum ( Figure 5(h) ). In vivo treatment of WT mice with GW501516 for two weeks significantly increased sAPPa content in hippocampus, but not in cortex and cerebellum ( Figure 5(i) ). GW501516 had no effect on sAPPa levels in all three brain regions derived from ePPARd À/À mice ( Figure 5(j) ). These results indicated that endothelial PPARd was critical for ADAM10 expression and sAPPa production in mouse cerebral microvessels, as well as sAPPa content in hippocampus.
It has been suggested that ADAM10 gene transcription is up-regulated by SIRT1 via activation of retinoid acid receptor/retinoid X receptor (RAR/RXR) heterodimers in neuroblastoma and neuroglioma cells. 47 (e) (f) Figure 5 . PPARd regulated ADAM10 expression and sAPPa production in vivo. (a) ADAM10 protein expression in brain microvasculature of ePPARd À/À mice is decreased. n ¼ 18, *P < 0.05, compared to wild type. (b) mRNA levels of ADAM10 in brain microvasculature of ePPARd À/À mice is reduced, in compared to wild type mice, n ¼ 5, *P < 0.05. (c) Protein levels of ADAM17 were increased in brain microvasculature of ePPARd À/À mice, n ¼ 4, *P < 0.05, compared to wild type. (d)-(f) The cerebral microvascular expression of ADAM9 (D, n ¼ 13), BACE1 (E, n ¼ 4), and APP (f, n ¼ 19) are not significantly different between WT and ePPARd À/À mice. (g) sAPPa production was decreased in cerebral microvessels of ePPARd À/À mice. Brain microvessels isolated from whole brain of ePPARd À/À and wild type mice were incubated in EBM2 containing 0.1% BSA for 24 h. The supernatants were collected for measuring sAPPa. n ¼ 17-19, P < 0.05. (h) Protein levels of sAPPa in brain regions. Note that in hippocampus of ePPARd À/À mice sAPPa level was decreased compared to WT mice (n ¼ 11, *P < 0.05). (i) In wild type mice, GW501516 treatment increased sAPPa protein level in hippocampus (n ¼ 10, *P < 0.05, compared to vehicle treatment). (j) In ePPARd À/À mice, GW501516 treatment did not affect sAPP a levels in all three brain regions (n ¼ 5).
It was also observed that SIRT1 gene transcription could be regulated by PPARd. 49, 50 Therefore, we further explored the relationship between PPARd, SIRT1, and ADAM10. In human BMECs, both iloprost and forskolin up-regulated SIRT1 protein levels (Figure 6(a) and (b) ), indicating that IP-cAMP signaling induced expression of ADAM10 might be mediated by SIRT1. Activation of PPARd using GW501516 also enhanced SIRT1 protein expression ( Figure 6(c) ), while PPARd-siRNA reduced SIRT1 protein levels ( Figure 6(d) ). PPARd-siRNA also blocked stimulatory effect of iloprost on expression of SIRT1 ( Figure 6(e) ), suggesting that PPARd mediates iloprost-induced SIRT1 expression. Notably, SIRT1-siRNA did not affect PPARd protein expression (Suppl. Figure 7) ; however, SIRT1-siRNA inhibited GW501516-induced expression of ADAM10 ( Figure 6(f) ), indicating that SIRT1 was downstream of PPARd in the ADAM10 regulation pathway (Figure 7) .
Discussion
In the present study, we report several novel findings. First, activation of IP-cAMP signaling pathway upregulates expression of APP and ADAM10 and stimulates production of sAPPa in human BMECs and Our previous studies have demonstrated that APP is highly expressed in vascular endothelium 13 thereby suggesting that intraluminal release of the products of APP processing from the endothelium may play an important role in vascular homeostasis and hemostasis. Most notably, previous studies have provided evidence that sAPPa released from the endothelium contains a KPI PPARd-siRNA or Ct-siRNA (30 nM) for two days, then treated with iloprost for three days. n ¼ 11, *P < 0.05, compared to other two groups. (f) Cells were incubated with SIRT1-siRNA or Ct-siRNA (50 nM) for two days, then treated with GW501516 (100 nM) for three days. n ¼ 12, *P < 0.05, compared to two other groups.
domain, an established anticoagulation factor. 12, 14 Our studies are the first to demonstrate that in human BMECs, activation of the IP-cAMP signaling pathway stimulates expression of APP and production of sAPPa, an anticoagulant and neuroprotective molecule derived from non-amyloidogenic processing of APP. In contrast, deletion of IP receptor in mouse reduces APP protein levels in cerebral microvessels, indicating an important in vivo role of IP-cAMP signaling in regulation of cerebrovascular expression of APP. The ADAMs are type 1 transmembrane proteins with endoproteolytic activities. By shedding the ectodomains of various membrane proteins, they are involved in physiological and pathological processes such as cell growth, adhesion, and migration. 17 Among all ADAMs, ADAM9, 10, and 17 participate in asecretase activity-mediated shedding of APP. 17 ADAM10 is responsible for the constitutive a-secretase activity in primary neurons, 51 and contributes to both constitutive and inducible a-secretase activity in the central nervous system. 52, 53 In vivo and in vitro studies suggest that the a-secretase activity of ADAM17 is primarily PKC-regulated (inducible activity). [54] [55] [56] It has been suggested that the ADAM9 is not able to directly cleave APP protein at a-secretase site, but that its a-secretase activity could be related to ADAM9 regulation of ADAM10 activity. 17, 57 We have detected all three ADAMs in mouse brain microvessels and human BMECs. Interestingly, endothelial deletion of PPARd in mouse decreased sAPPa production, accompanied by a significant reduction of ADAM10 expression and increased ADAM17 protein level, indicating that in brain microvessels sAPPa production is primarily determined by activity of ADAM10. The mechanisms underlying increased ADAM17 expression in brain microvessels of ePPARd À/À mice is unknown and remains to be determined. Of note, in vitro knockdown of PPARd in human BMECs did not change ADAM17 expression. We do not have an explanation for discrepancy between in vivo and in vitro results, other than the possibility that species difference or experimental conditions may account for our observations.
PPARd belongs to the nuclear hormone receptor family of ligand-activated transcription factors. 8 PPARd is ubiquitously expressed in various tissues, including the vasculature, and plays important roles in the regulation of lipid and glucose metabolism, inhibition of inflammation, and improvement of insulin sensitivity. 8 Preclinical experiments also demonstrated strong vascular protective effects of PPARd agonists. 8 Our previous studies have demonstrated that endogenous PGI 2 -dependent angiogenesis is at least in part mediated by activation of PPARd. 31 In addition, activation of PPARd protects cerebral microvasculature from oxidative stress, 33 indicating that activity of PPARd may play a critical vascular protective role in the cerebral circulation. Our current findings revealed a previously unrecognized role of PPARd in the regulation of ADAM10 in the cerebral microvessels. We demonstrated that PPARd-siRNA abolished iloprostinduced expression of ADAM10, indicating that PPARd was a major mediator of the iloprost-induced expression of ADAM10. Since cAMP signaling has been shown to activate PPARd, 8, 45, 46 it is likely that activation of IP-cAMP signaling augments ADAM10 expression via activation of PPARd (Figure 7 ). It has also been reported that in vitro both PGI 2 and iloprost could directly bind to PPARd, 8, 58, 59 therefore, we cannot rule out the possibility that direct activation of PPARd by iloprost might contribute to increase in expression of ADAM10.
We also observed that iloprost and forskolin augmented SIRT1 protein levels in endothelial cells. This finding is consistent with the results of a previous study demonstrating that in mouse carotid arteries activation of IP receptors activates SIRT1. 60 Our findings indicate that SIRT1 may also mediate iloprost and cAMP signaling-induced up-regulation of ADAM10. Since iloprost augmented ADAM10 protein expression via PPARd-SIRT1 pathway, and activation of PPARd by GW501516 also increased SIRT1 protein levels, it is likely that IP-cAMP activation stimulated PPARd-SIRT1 leading to up-regulation of ADAM10. Though it has been reported that cAMP/PKA signaling phosphorylates and activates SIRT1, 61 our results demonstrating that deletion of PPARd completely inhibit the effect of iloprost on expression of ADAM10 suggest that direct activation of SIRT1 by cAMP/PKA leading to stimulation of ADAM10 expression is unlikely a dominant pathway in our experimental model. Rather, our observations suggest that PPARd activated by IP-cAMP signaling or directly by binding of IP ligands (such as iloprost and PGI 2 ), stimulates SIRT1 activity and consequently up-regulates expression of ADAM10 (Figure 7 ). We do not have an explanation as to why activation of PPARd by GW501516 increases production of sAPPa but does not affect protein expression of APP. It has been reported that both ubiquitin dependent and independent mechanisms of proteasome mediate APP degradation, 62 and that PPAR isoforms regulate proteosomal degradation. 63 Therefore, it is possible that GW501516 may also affect metabolism of APP via proteasome system 62,63 thereby preserving apparently normal protein levels of APP despite increased a-processing of APP. We also wish to point out that similar to our findings in endothelium, previous studies in neuronal tissue reported that activation of protein kinase C increased production of sAPPa without affecting expression of APP protein. 64, 65 The exact mechanisms responsible for discrepancy between increased generation of sAPPa and preservation of APP protein expression are currently unknown and remain to be determined.
Relevant to our study, it has been shown that reduction of cholesterol promotes APP processing via the non-amyloidogenic -secretase pathway, increasing the formation of sAPPa, and decreasing A production. 66 Our previous studies have revealed that ePPARd À/À mice have normal lipid profile, 32 therefore ruling out the possibility that suppressed ADAM10 expression in cerebral microvessels of ePPARd À/À mice is caused by changes in lipid profile. Moreover, experiments in cultured human BMECs indicated that PPARd up-regulated ADAM10 expression, thus minimizing the possibility that systemic factors were involved in reduced expression of ADAM10 in ePPARd À/À mice.
Endothelium-derived PGI 2 is an essential molecule responsible for preservation of cerebrovascular homeostasis under pathological conditions when blood vessels are exposed to injury induced by stroke, inflammation, and brain trauma. [1] [2] [3] 6, 7, 43, 44 Indeed, PGI 2 has been identified as a major protective product of arachidonic acid metabolism within the vasculature. 6 In the cerebral circulation, elevated production of PGI 2 in response to vascular injury is designed to prevent aggregation of platelets, to preserve blood flow, and to inhibit aberrant remodeling of injured vascular wall. 3, 34 However, no previous studies have addressed the role of PGI 2 in regulation of APP processing. Recognition of the ability of PGI 2 to regulate expression and non-amyloidogenic processing of APP suggests that this mechanism might be an important contributor to overall neurovascular protective functions of PGI 2 .
Prior studies established that activation of IP receptors exerts neuro-protective effects during focal cerebral ischemia, transient global cerebral ischemia, and traumatic brain injury. 3, 43, 44, 67 Moreover, systemic administration of PGI 2 analogue, beraprost, attenuated neuronal damage caused by ischemic stroke 67 thereby suggesting that activation of vascular IP receptors may contribute to tissue protective effects of beraprost. In the present study, we provide in vitro evidence that activation of IP receptors increases expression and a-processing of APP and generation of neuroprotective and anticoagulant cleavage product sAPPa. Moreover, we found that hippocampal sAPPa was significantly reduced in IP À/À mice. These findings are in agreement with previous observations that impairment of PGI 2 signaling enhances loss of neuronal cell in hippocampus exposed to brain ischemia or traumatic brain injury, 43, 44 conditions known to be associated with neuro-protective activation of COX2-PGI 2 signaling. 3, 7, 68 In line with our findings regarding an important role of PPARd in production of sAPPa, previous studies also demonstrated that activation of PPARd reduces ischemia-induced brain vascular endothelial injury, 69 and attenuates injury induced by ischemic stroke. 70 Moreover, previous study established important role of PPARd/SIRT1 activation in anticoagulant effect of PGI 2 . 71 Another notable prior observation was that PPARd agonist, GW501516, improved spatial memory in wild type mice under physiological conditions. 72 Consistent with this observation, we found that systemic administration of GW501516 increased levels of sAPPa in hippocampus. Since sAPPa level was decreased in hippocampus of in ePPARd À/À mice, and loss of endothelial PPARd abolished GW501516induced increase of hippocampal sAPPa, PPARd signaling in cerebrovascular endothelium appears to be responsible for the changes of sAPPa content in hippocampus. This explanation is also consistent with prior findings demonstrating that GW501516 does not cross blood-brain barrier. 73 At the present time, the reasons for selective elevation of sAPPa in hippocampus are unknown. However, findings from several prior studies are relevant for understanding of our observations: (a) vascular architecture and function may vary in different brain regions, 74 (b) albumin can access the parenchyma of the hippocampus under normal conditions, 75 and (c) different transport rates of chemokine in different brain regions have been reported. 76 Moreover, a distinguished feature of subgranular zone of hippocampus is that angiogenesis and neurogenesis are tightly coupled 74 thereby maintaining strong interaction between vascular and neuronal compartment. These findings imply that in hippocampus, large proteins including sAPPa produced in endothelium might have access to neuronal tissue. In addition, activation of PPARd may exert more pronounced effect in hippocampal microvessels as compared to microvessels derived from other brain regions. Of note, it has been reported that in hippocampus exercise stimulates angiogenesis and neurogenesis. 74, 77, 78 Since activation of PPARd mimics beneficial effects of exercise, 79,80 it is possible that hippocampal vasculature is generally more dependent on activation of PPARd for production of sAPPa. In aggregate, our findings provide new insights into signal transduction mechanisms that might help to explain therapeutic effects of PPARd agonists. 81 In the present study, we provide in vitro and in vivo evidence that in cerebral microvessels activation of IP receptors promotes expression and a-processing of APP. Our results suggest that in hippocampus, endothelial PPARd mediates IP signaling-induced production of sAPPa. These findings have important implications for understanding the mechanisms underlying neurovascular protective function of PGI 2 .
